Literature DB >> 33993627

The use of human acellular dermal matrices in advanced wound healing and surgical procedures: State of the art.

Linda Tognetti1, Elisa Pianigiani1, Francesca Ierardi1, Guido Lorenzini2, Donato Casella3, Flavio Giulio Liso1, Andrea De Pascalis1, Elisa Cinotti1, Pietro Rubegni1.   

Abstract

Wound closure after post-traumatic injuries and/or localized at peculiar body sites (head-and-neck, oral cavity, legs) are particularly challenging and can often be delayed due to local and systemic factors. In case of deep wounds and/or hard-to-heal wounds, grafting of dermal acellular matrices (ADM) is often needed. Though a great variety of synthetic and semisynthetic dermal and skin equivalents are available, viable human dermis, is still considered the most physiological alternative to replace the loss of autologous dermis, by acting as a physiological scaffold that add structural support to soft tissues. To date, human ADMs (hADMs) have been employed in the reconstruction of skin defects affecting almost all body sites, ranging from visceral sites to the skin and subcutaneous tissues. This review aims to investigate the use of hADM at different body sites and their peculiar advantages. A literature search was using the search terms "acellular dermal matrices", "dermal regeneration", "advances wound healing", "human acellular dermal matrices surgery". A total of 50 out of 150 papers was included. Based on the current body if evidence, hADMs appear to bring several advantages, such as: protection of deep structures (eg, tendons, bones, cartilage and nerves); stimulation of a functional new dermis (rather than a scar); reduction of wound closure time; control of pain and exudate. Finally, hADMs may represent the best treatment option for hard-to-heal wound not only in terms of efficacy and patient satisfaction bout also in terms of sanitary costs, especially across Europe, where hADMs cannot be commercialized as medical devices.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  acellular dermal matrix; surgery; tissue engineering; ulcers; wound healing

Year:  2021        PMID: 33993627     DOI: 10.1111/dth.14987

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  6 in total

Review 1.  Skin substitutes for the management of mohs micrographic surgery wounds: a systematic review.

Authors:  Kimberly W Lu; Amor Khachemoune
Journal:  Arch Dermatol Res       Date:  2022-02-15       Impact factor: 3.017

2.  Evaluation of Paste-Type Micronized Acellular Dermal Matrix for Soft Tissue Augmentation: Volumetric and Histological Assessment in a Mouse Model.

Authors:  Lan Sook Chang; Seung Hwan Kim; Hyunsung Kim; Soorack Ryu; Young Bin Choy; Sang Wha Kim
Journal:  Aesthetic Plast Surg       Date:  2022-08-30       Impact factor: 2.708

3.  Constructing Tissue-Engineered Dressing Membranes with Adipose-Derived Stem Cells and Acellular Dermal Matrix for Diabetic Wound Healing: A Comparative Study of Hypoxia- or Normoxia-Culture Modes.

Authors:  Wen Zhou; Xin Zhao; Xin Shi; Can Chen; Yanpeng Cao; Jun Liu
Journal:  Stem Cells Int       Date:  2022-05-05       Impact factor: 5.131

4.  Application of Allogeneic Human Acellular Dermal Matrix Reduces the Incidence of Fistula in Hypospadias Repair.

Authors:  Shijian Wu; Chenglong Ye; Huai Yang; Bote Chen; Haibo Nie; Shaowei Li
Journal:  Front Pediatr       Date:  2022-03-09       Impact factor: 3.418

5.  A Prospective Randomized Controlled Multicenter Clinical Trial Comparing Paste-Type Acellular Dermal Matrix to Standard Care for the Treatment of Chronic Wounds.

Authors:  Youn Hwan Kim; Hyung Sup Shim; Jihye Lee; Sang Wha Kim
Journal:  J Clin Med       Date:  2022-04-14       Impact factor: 4.964

6.  Frozen bean curd-inspired xenogeneic acellular dermal matrix with triple pretreatment approach of freeze-thaw, laser drilling and ADSCs pre-culture for promoting early vascularization and integration.

Authors:  Xing Huang; Zhu Zhu; Lin Lu; Rui Jin; Di Sun; Xusong Luo
Journal:  Regen Biomater       Date:  2022-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.